Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer Journal Article
| Authors: | Kemeny, N.; Cohen, A.; Seiter, K.; Conti, J. A.; Sigurdson, E. R.; Tao, Y.; Niedzwiecki, D.; Botet, J.; Budd, A. |
| Article Title: | Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer |
| Abstract: | Purpose: This study was designed to determine if hepatic arterial therapy with floxuridine (F), mitomycin, and carmustine (BCNU) (FMB) is superior to hepatic arterial therapy with F alone in previously treated patients with hepatic metastases from colorectal cancer. Patients and Methods: Ninety-five patients were randomized to intrahepatic FMB versus intrahepatic F. All patients had tumor progression after systemic chemotherapy (either therapeutic or adjuvant). Results: There was no significant difference in response rate (47% FMB v 33% F; P = .17). Median survival was similar in the two groups, 19.1 months for the FMB group compared with 14.0 months for the F group (P = .23). The overall median survival was 16.8 months. In patients who received prior adjuvant therapy, there was no difference between the two groups, but response rate was high in both (50% FMB v 62% F). The response rate for all patients who had received only prior adjuvant therapy versus all those who had received prior therapy for metastatic disease was 57% and 35%, respectively (P = .066). In the subset of patients whose disease had progressed with prior systemic chemotherapy, the response rate to FMB was greater than that to F (47% v 23%; P = .035). Conclusion: The overall partial response rate of 39% and the overall survival of 16.8 months from initiation of intrahepatitis therapy show that hepatic arterial therapy is a reasonable treatment option for patients whose tumor does not respond to systemic therapy or whose disease progresses after adjuvant therapy for colorectal cancer. © 1993 by American Society of Clinical Oncology. |
| Keywords: | adult; cancer survival; treatment outcome; aged; aged, 80 and over; survival analysis; major clinical study; cancer combination chemotherapy; drug efficacy; liver neoplasms; adjuvant therapy; comparative study; colorectal cancer; phase 2 clinical trial; antineoplastic combined chemotherapy protocols; carmustine; colorectal neoplasms; liver metastasis; intraarterial drug administration; infusions, intra-arterial; mitomycin; floxuridine; hepatic artery; middle age; mitomycins; human; male; female; priority journal; article; support, u.s. gov't, p.h.s. |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 11 |
| Issue: | 2 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 1993-02-01 |
| Start Page: | 330 |
| End Page: | 335 |
| Language: | English |
| DOI: | 10.1200/jco.1993.11.2.330 |
| PUBMED: | 8426211 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 March 2019 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work